The human T cell lymphotrophic virus type I (HTLV-I) has recently been identified in a T cell lymphoma associated with hypercalcemia and increased bone turnover. Since increased serum concentrations of 1,25-dihydroxyvitamin D have been reported in this disease, we have examined the capacity of HTLV-I-infected cord blood lymphocytes to metabolize 25-hydroxyvitamin D3. Our results demonstrate that HTLV-I-infected cells have the capacity to metabolize 25-hydroxyvitamin D3 to a substance that co-migrates with 1,25-dihydroxyvitamin D3 by high performance liquid chromatography over a silica column using either 12% isopropanol in hexane or 5% isopropanol in dichloromethane. The metabolite binds to the 1,25-dihydroxyvitamin D3 receptor in rat osteosarcoma cells and stimulates bone resorption in cultures of fetal rat long bones. Mass spectrometric analysis of the metabolite confirmed the presence of 1,25-dihydroxyvitamin D3. Production of 1,25-dihydroxyvitamin D by lymphoma cells may contribute to the pathogenesis of the hypercalcemia seen in patients with HTLV-I-associated T cell lymphomas.
Introduction
The human T cell lymphotrophic virus type I (HTLV-I)' is a type C retrovirus that has recently been associated with a peculiar form of T cell lymphoma described in patients in the United States, Japan, and the West Indies (1) . This tumor is characterized clinically by lymphocytosis, hepatosplenomegaly, and a particularly aggressive clinical course (1) . Since hypercalcemia is an infrequent complication of most malignancies, it is remarkable that almost all of the patients studied to date with HTLV-I- 1 . Abbreviations used in this paper: 25(OH)D3, 25-hydroxyvitamin D3; 1,25(OH)2D, 1,25-dihydroxyvitamin D; HPLC, high performance liquid chromatography; HTLV-I, human T cell lymphotrophic virus type I; OAF, osteoclast-activating factor. associated T cell lymphomas have developed a syndrome of increased bone turnover and hypercalcemia at some time during the course of their disease. Bone biopsies showing increased osteoclast activity in the absence of tumor invasion, and the induction of bone resorption by conditioned media harvested from tumor cells in vitro, strongly suggest that the hypercalcemia seen in this disorder is mediated by a humoral mechanism (2) . The finding of increased circulating concentrations of 1,25-dihydroxyvitamin D [1, 25(OH) 2D] in a patient with HTLV-I-positive lymphoma has raised the possibility that production of 1,25(OH)2D by tumor lymphocytes may play a role in the pathogenesis of the hypercalcemia seen in this disorder (3) . Accordingly, the purpose ofthis study was to examine the possibility that HTLV-I-transformed T lymphocytes have the capacity to convert 25-hydroxyvitamin D3 [25(OH)D3] to 1,25(OH)2D3.
Human cord blood T lymphocytes immortalized by the HTLV-I virus after co-cultivation with lymphoma cells carrying this virus have been used as a model to study the characteristics of HTLV-I-induced neoplastic transformation (4, 5) . These transformed cord blood cells express HTLV-I proteins and have identical morphologic and functional properties to the neoplastic T cells (4, 5) . They have been shown to contain lobulated nuclei, to retain the potential for indefinite growth, and to demonstrate surface receptor characteristics and lymphokine production that match those of the HTLV-I-infected lymphoma cells (5).
Methods
Cells. The cord blood lymphocytes infected with HTLV-I used in these studies were the C91/PL cell line. The cells were analyzed for expression ofHTLV antigens, extracellular virus, karyotype, and HLA profiles. The cells were shown to assume the morphologic and functional characteristics of the parent lymphoma cells and have been in continuous culture for several years (4, 5) .
Metabolite production. The capacity ofthe virus-infected transformed cord blood lymphocytes to metabolize 25(OH)D3 was determined in vitro. The cells were grown to a density of -106 cells/ml in 10 ml of RPMI 1640 medium (KC Biological, Inc., Lenexa, KA) supplemented with 10% fetal bovine serum. The culture medium was replaced with serum-free RPMI 1640 medium 48 h before each assay. The cells were then incubated with -200,000 dpm (1 pmol) 3H-25(OH)D3 (25-hydroxy-26,27-methyl-3H-cholecalciferol, 170 Ci/mmol, Amersham Corp., Ar- lington Heights, IL) for a period of 24 h. At the end of this incubation the cells and medium were harvested, and the 25(0H)D3 metabolites were extracted into 5 ml ofacetonitrile. After the addition of5 ml K2HPO4 buffer (0.4 M, pH 10.6), the extract was applied directly to a prewashed C18 Sep Pak cartridge (Waters Assoc., Millipore Corp., Milford, MA). The cartridge was then washed with 5 ml of distilled water followed by 3 Receptor assay. Binding of the purified 25(OH)D3 metabolite to the intracellular 1,25(OH)2D receptor was determined using rat osteosarcoma cells as previously described (7) .
Bone resorption assay. The capacity of the purified 25(OH)D3 metabolite to stimulate bone resorption in vitro was examined using a bioassay of fetal rat long bones in organ culture (8) , in the presence or absence of the 25(OH)D3 metabolite, for a period of 48 h. Results are expressed as the ratio of the percent of the total "Ca released in the test groups compared to the percent of the toa'Ca released in the control group. Differences between control and test groups were analyzed using the Student's t test for nonpaired samples.
Mass spectrometry. The HTLV-I metabolite produced by incubating 25(OH)D3 (1 ug) with HTLV-I-transformed cord blood lymphocytes was purified by two consecutive HPLC runs using 12% isopropanol in hexane. 1H-,25(OH)2D3 (10,000 dpm or 0.1I pmnol) was added to each sample as an internal marker before purification by HPLC. Approximately 50 ng of 1,25(OH)2D3 or the purified vitamin D3 metabolite were placed in separate reaction vials with 20 Ml N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA; Pierce Chemical Co., Rockford, IL) and heated at 60'C for 10 min. Gas chromatographic separation of the trimethylsilyl ether derivatives was accomplished with a 1 5-in X 0.32-mm iW. BP-lI fused silica column (Scientific Glass Engineering Inc., Austin, TX) heated from 270'C to 280'C at 50C/min after injection. Samples (10 Ml) were introduced by means of a glass falling needle injector (R. H. Allen Co.) at an injection port temperature of 250'C. The head pressure of the helium carrier gas was 4 psi and the exit flow from the injector was 2 mI/mmn. The effluent from the gas chromatograph was admitted directly into the mass spectrometer through a heated transfer line, which was maintained at 250'C. Positive ion electron impact (70 eV) mass spectrometry was performed on a Finnigan-MAT 212 mass spectrometer in combination with an INCOS 2200 data system. The ion source temperature was 2500C for the gas chromatography mass spectrometric analyses and 150'C for the direct insertion probe studies. The accelerating voltage was 3 kV.
Results
The elution pattern of the 25(OH)D3 metabolite produced by incubation of 3H-25(OH)D3 with HTLV-I-transformed cord blood lymphocytes revealed a peak of radioactivity that eluted with the same retention time as 1 ,25(OH)2D3 by HPLC over a silica column using 12% isopropanol in hexane (Fig. 1) (Fig. 3) . Moreover, when the 5,000-'S 3p00- lymphocytes (solid line) compared with that of 1,25(OH)2D3 (broken line). Fraction 9 (elution volume 17-18 ml), which co-eluted with 1,25(OH)2D3 from a silica column using 12% isopropanol in hexane (Fig. 1) , was rechromatographed on a silica column using 5% isopropanol in dichloromethane at a flow rate of 1 ml/min. The elution pattern of unlabeled 1,25(OH)2D3 was determined simultaneously by ul- purified 25(OH)D3 metabolite was incubated in a bone resorption assay system, there was a significant increase in the amount of 45Ca released in bones exposed to media containing the 25(OH)D3 metabolite compared with those bones exposed to control media alone (Table I) . Similar effects on bone resorption were produced by 1,25(0H)2D3 at concentrations of I0-8'M. While it seemed unlikely that another 25(OH)D3 metabolite could exhibit the same chromatographic and biological characteristics as 1,25(OH)2D3, identification of this metabolite remained speculative until its molecular structure was confirmed. Mass spectrometric analysis of the 25(OH)D3 metabolite'that eluted with the same retention time as 1,25(OH)2D3 over two HPLC runs using 12% isopropanol in hexane was performed. Fig. 4 shows the mass spectra obtained from the trimethylsilyl derivatives of standard 1,25(OH)2D3 (Fig. 4, top) and the metabolite (Fig. 4, bottom) after introduction by means of a direct insertion probe. Excellent agreement was seen not only between the spectra shown in Fig. 4 but also with previously published results (1 1 groups are present on the "A" ring; and m/z 131, which reflects hydroxylation at the 25-position. Further evaluation of the chemical nature of the metabolite was obtained by gas chromatography-mass spectrometry. It has previously been shown that 1,25(OH)2D3 can thermally rearrange to form two sterol isomers (12) . These isomers, called the pyro and isopyro forms, are seen as two distinct gas chromatographic peaks. Both the standard and the metabolite behaved in this manner under the conditions of the present study, yielding peaks with retention times of 5.0 min (pyro) and 5.8 min (isopyro). The spectra for the major isomer (pyro) are shown in Fig. 5 . Again the spectrum from the metabolite closely matched that ofthe standard. Thus, the identity of the metabolite as 1,25(OH)2D3 is further substantiated by the agreement with the thermal reactivity and gas chromatographic behavior ofthe standard and the mass spectra of the trimethylsilyl derivatives. 
Discussion
The data presented here indicate that cord blood lymphocytes infected with HTLV-I, which behave in culture as HTLV-Iassociated lymphoma cells, have the capacity to metabolize 25(OH)D3 to 1,25(OH)2D3. It appears likely that hypercalcemia in HTLV-I-associated lymphoma may in part be caused by increased production of 1,25(OH)2D by lymphoma cells.
Although the primary site of the l-alpha-hydroxylase enzyme required for the conversion of 25(OH)D to 1,25(OH)2D is the kidney, there is increasing evidence for extrarenal sites as well.
l-Alpha-hydroxylase activity has been reported in various tissues including the placenta (13, 14) , chick chorion (15), rabbit and human bone cells (16, 17) , melanoma cells (18) (22) . Sarcoidosis is characterized by abnormal T cell function and increased numbers ofactivated T lymphocytes of the mature helper-suppressor type in the lung (22) . It is attractive to speculate that activated lymphocytes, in addition to pulmonary alveolar macrophages in patients with sarcoidosis, may contribute to the increased circulating concentrations of 1,25(OH)2D seen in both of these diseases.
The clinical syndrome of T cell lymphoma characterized by hypercalcemia and the presence of antibodies to HTLV-I is of interest for several reasons. In contrast to nonvirus-associated lymphoma, these patients frequently have an aggressive, rapidly fatal course characterized by a paraneoplastic syndrome of increased bone turnover with hypercalcemia. One recent study reported that 5 of 11 patients with HTLV-I antibody-positive lymphoma presented with manifestations of hypercalcemia (1) , and all 11 patients developed hypercalcemia at some time during the course of this disease. While some patients have had lytic bone lesions on radiographs, biopsy of these lesions has often failed to reveal tumor involvement and showed only increased osteoclast activity (2) (3) (4) (5) 
